Alyeska Investment Group
RIGL icon

Alyeska Investment Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Alyeska Investment Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-40,028
Closed -$1.32M – 535
2017
Q1 		$1.32M Buy
+40,028
New +$1.02M 0.01% 422

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group's RIGL Position: Q2 2017 in Review

Alyeska Investment Group sold out of Rigel Pharmaceuticals (RIGL) in Q2 2017, closing a stake of 40,028 shares — an estimated $1.32M sold.

Alyeska Investment Group first reported a position in RIGL in Q1 2017 and held it in 1 quarter. The position peaked at $1.32M in Q1 2017. 110 funds tracked by Wall St. Rank hold RIGL as of Q2 2017.

  • Alyeska Investment Group reported no remaining Rigel Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 40,028 Rigel Pharmaceuticals shares in Q2 2017, an estimated $1.32M.
  • Alyeska Investment Group first reported a position in Rigel Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Alyeska Investment Group's Rigel Pharmaceuticals position peaked at $1.32M in Q1 2017.
  • 110 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2017.

Based on Alyeska Investment Group's 13F filing for Q2 2017, filed 14 Aug 2017.